Skip to content

Transcutaneous Electrical Acustimulation (TEA) for Patients with Functional Constipation: A Multicenter, Randomized, Double-Blind, Sham-Controlled Trial

Transcutaneous Electrical Acustimulation (TEA) for Patients with Functional Constipation: A Multicenter, Randomized, Double-Blind, Sham-Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129438
Enrollment
Unknown
Registered
2026-08-04
Start date
2026-08-10
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional constipation

Interventions

TEA treatment group:zusanli stimulation
Sham-TEA treatment group:sham electrical stimulation

Sponsors

Hainan Medical College First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged 18 to 75 years, regardless of gender; 2. Patients with functional constipation meeting the Rome IV criteria (fewer than 3 complete spontaneous bowel movements per week); 3. TEA treatment can be self-administered at home by the patients; 4. Voluntarily participate in this trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of colorectal diseases (inflammatory bowel disease, toxic colitis, toxic megacolon, volvulus, Hirschsprung's disease, and idiopathic intestinal pseudo-obstruction); 2. Previous gastrointestinal surgery that altered the anatomical structure of the gastrointestinal tract; 3. Constipation caused by systemic diseases (e.g., diabetes mellitus, Parkinson's disease); 4. Inability to maintain a stable medication regimen during the study period; 5. Irritable Bowel Syndrome with Constipation; 6. Severe heart failure, liver failure, renal failure, acute stroke, uncontrolled diabetes mellitus, or hyperthyroidism; 7. Presence of implanted electrical stimulation devices, such as cardiac pacemakers, coronary artery stents, or other implants that may be affected by electrical stimulation; 8. Allergy to electrode patches; 9. Women who are currently pregnant or breastfeeding; 10. Inability to comply with the study protocol due to illness, severe cognitive impairment, psychiatric disorders, geographical distance, or other factors as determined by the research team; 11. Infection, bleeding, or scarring at the treatment site; 12. Familiar with acupuncture treatment, acupoints or meridians; 13. Participation in other interventional clinical trials within the past 90 days.

Design outcomes

Secondary

MeasureTime frame
Patient Assessment of Constipation – Quality of Life Questionnaire(PAC-QOL);Upper gastrointestinal symptoms (GCSI);Hospital Anxiety and Depression Scale (HADS);Patient Assessment of Constipation – Symptoms Questionnaire(PAC-SYM);Weekly frequency of complete spontaneous bowel movements (CSBMs) and spontaneous bowel movements (SBMs);Bristol Stool Form Scale;

Primary

MeasureTime frame
Proportion of patients with 3 or more complete spontaneous bowel movements per week at week 4 of treatment.;

Countries

China

Contacts

Public ContactYan Tan

Hainan Medical College First Affiliated Hospital

tanyan_cg@126.com+86 898 66528102

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026